BACKGROUND: The therapeutic gold standard of muscle-invasive tumour stages is radical cystectomy (RC), but there are still conflicting reports about associated morbidity and mortality and the oncologic benefit of RC in elderly patients. The aim of the present study was the comparison of overall (OS) and cancer-specific survival (CSS) in patients <75 and >75 years of age (median follow-up was 42 months). PATIENTS AND METHODS: Clinical and histopathological data of 2,483 patients with urothelial carcinoma and consecutive RC were collated. The study group was dichotomized by the age of 75 years at RC. Statistical analyses comprising an assessment of postoperative mortality within 90 days, OS and CSS were assessed. Multivariate logistic regression and survival analyses were performed. RESULTS: The 402 patients (16.2%) with an age of ≥75 years at RC showed a significantly higher local tumour stage (pT3/4 and/or pN+) (58 vs 51%; p=0.01), higher tumour grade (73 vs 65%; p=0.003) and higher rates of upstaging in the RC specimen (55 vs 48%; p=0.032). Elderly patients received significantly less often adjuvant chemotherapy (8 vs 15%; p<0.001). The 90-day mortality was significantly higher in patients ≥75 years (6.2 vs 3.7%; p=0.026). When adjusted for different variables (gender, tumour stage, adjuvant chemotherapy, time period of RC), only in male patients and locally advanced tumour stages was an association with 90-day mortality noticed. The multivariate analysis showed that patients ≥75 years of age have a significantly worse OS (HR=1.42; p<0.001) and CSS (HR=1.27; p=0.018). CONCLUSIONS: An age of ≥75 years at RC is associated with a worse outcome. Prospective analyses including an assessment of the role of comorbidity and possibly age-dependent tumour biology are warranted.
BACKGROUND: The therapeutic gold standard of muscle-invasive tumour stages is radical cystectomy (RC), but there are still conflicting reports about associated morbidity and mortality and the oncologic benefit of RC in elderly patients. The aim of the present study was the comparison of overall (OS) and cancer-specific survival (CSS) in patients <75 and >75 years of age (median follow-up was 42 months). PATIENTS AND METHODS: Clinical and histopathological data of 2,483 patients with urothelial carcinoma and consecutive RC were collated. The study group was dichotomized by the age of 75 years at RC. Statistical analyses comprising an assessment of postoperative mortality within 90 days, OS and CSS were assessed. Multivariate logistic regression and survival analyses were performed. RESULTS: The 402 patients (16.2%) with an age of ≥75 years at RC showed a significantly higher local tumour stage (pT3/4 and/or pN+) (58 vs 51%; p=0.01), higher tumour grade (73 vs 65%; p=0.003) and higher rates of upstaging in the RC specimen (55 vs 48%; p=0.032). Elderly patients received significantly less often adjuvant chemotherapy (8 vs 15%; p<0.001). The 90-day mortality was significantly higher in patients ≥75 years (6.2 vs 3.7%; p=0.026). When adjusted for different variables (gender, tumour stage, adjuvant chemotherapy, time period of RC), only in male patients and locally advanced tumour stages was an association with 90-day mortality noticed. The multivariate analysis showed that patients ≥75 years of age have a significantly worse OS (HR=1.42; p<0.001) and CSS (HR=1.27; p=0.018). CONCLUSIONS: An age of ≥75 years at RC is associated with a worse outcome. Prospective analyses including an assessment of the role of comorbidity and possibly age-dependent tumour biology are warranted.
Authors: M Retz; J Lehmann; C Trocha; T Loch; U Seppelt; C Fischer; F A Pinkenburg; K J Timm; S Wellek; M Stöckle Journal: Cancer Date: 2000-09-01 Impact factor: 6.860
Authors: Matthew E Nielsen; Shahrokh F Shariat; Pierre I Karakiewicz; Yair Lotan; Craig G Rogers; Gilad E Amiel; Patrick J Bastian; Amnon Vazina; Amit Gupta; Seth P Lerner; Arthur I Sagalowsky; Mark P Schoenberg; Ganesh S Palapattu Journal: Eur Urol Date: 2006-11-13 Impact factor: 20.096
Authors: George R Prout; Margaret N Wesley; Rosemary Yancik; Lynn A G Ries; Richard J Havlik; Brenda K Edwards Journal: Cancer Date: 2005-10-15 Impact factor: 6.860
Authors: Derya Tilki; Dirk Zaak; Matthias Trottmann; Alexander Buchner; Yeliz Ekiz; Niklas Gerwens; Boris Schlenker; Alexander Karl; Sebastian Walther; Patrick J Bastian; Christian Gratzke; Stefan Tritschler; Ruth Knüchel-Clarke; Süleyman Ergün; Christian G Stief; Oliver Reich; Michael Seitz Journal: World J Urol Date: 2009-10-22 Impact factor: 4.226
Authors: G Hatiboglu; J Huber; E Herpel; I V Popeneciu; J Nyarangi-Dix; D Teber; B A Hadaschik; S Pahernik; S Duensing; M Hohenfellner Journal: Urologe A Date: 2015-09 Impact factor: 0.639
Authors: M W Kramer; M Wolters; I F Abdelkawi; A S Merseburger; U Nagele; A Gross; T Bach; M A Kuczyk; T R W Herrmann Journal: Urologe A Date: 2012-06 Impact factor: 0.639